It is the raw material for drugs used to treat tumor diseases.
LPI (LP Information)' newest research report, the “Antitumor API Industry Forecast” looks at past sales and reviews total world Antitumor API sales in 2022, providing a comprehensive analysis by region and market sector of projected Antitumor API sales for 2023 through 2029. With Antitumor API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antitumor API industry.
This Insight Report provides a comprehensive analysis of the global Antitumor API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antitumor API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Antitumor API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antitumor API and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antitumor API.
The global Antitumor API market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Antitumor API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Antitumor API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Antitumor API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Antitumor API players cover Acebright, Tapi Teva, Heraeus, Johson Matthey, Vinkem Labs, Chem Genix, Cipla, Qilu Pharmaceutial and Hangzhou Haoke Bio-Tech, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Antitumor API market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Digestive System Tumor API
Genitourinary System Tumor API
Other
Segmentation by application
Injection
Oral Medicine
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Acebright
Tapi Teva
Heraeus
Johson Matthey
Vinkem Labs
Chem Genix
Cipla
Qilu Pharmaceutial
Hangzhou Haoke Bio-Tech
Kunming Guiyan Pharmaceutical
Apotex Pharmachem
Dr. Reddy's Laboratories
Umicore
Key Questions Addressed in this Report
What is the 10-year outlook for the global Antitumor API market?
What factors are driving Antitumor API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Antitumor API market opportunities vary by end market size?
How does Antitumor API break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Antitumor API Annual Sales 2018-2029 2.1.2 World Current & Future Analysis for Antitumor API by Geographic Region, 2018, 2022 & 2029 2.1.3 World Current & Future Analysis for Antitumor API by Country/Region, 2018, 2022 & 2029 2.2 Antitumor API Segment by Type 2.2.1 Digestive System Tumor API 2.2.2 Genitourinary System Tumor API 2.2.3 Other 2.3 Antitumor API Sales by Type 2.3.1 Global Antitumor API Sales Market Share by Type (2018-2023) 2.3.2 Global Antitumor API Revenue and Market Share by Type (2018-2023) 2.3.3 Global Antitumor API Sale Price by Type (2018-2023) 2.4 Antitumor API Segment by Application 2.4.1 Injection 2.4.2 Oral Medicine 2.5 Antitumor API Sales by Application 2.5.1 Global Antitumor API Sale Market Share by Application (2018-2023) 2.5.2 Global Antitumor API Revenue and Market Share by Application (2018-2023) 2.5.3 Global Antitumor API Sale Price by Application (2018-2023) 3 Global Antitumor API by Company 3.1 Global Antitumor API Breakdown Data by Company 3.1.1 Global Antitumor API Annual Sales by Company (2018-2023) 3.1.2 Global Antitumor API Sales Market Share by Company (2018-2023) 3.2 Global Antitumor API Annual Revenue by Company (2018-2023) 3.2.1 Global Antitumor API Revenue by Company (2018-2023) 3.2.2 Global Antitumor API Revenue Market Share by Company (2018-2023) 3.3 Global Antitumor API Sale Price by Company 3.4 Key Manufacturers Antitumor API Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Antitumor API Product Location Distribution 3.4.2 Players Antitumor API Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023) 3.6 New Products and Potential Entrants 3.7 Mergers & Acquisitions, Expansion 4 World Historic Review for Antitumor API by Geographic Region 4.1 World Historic Antitumor API Market Size by Geographic Region (2018-2023) 4.1.1 Global Antitumor API Annual Sales by Geographic Region (2018-2023) 4.1.2 Global Antitumor API Annual Revenue by Geographic Region (2018-2023) 4.2 World Historic Antitumor API Market Size by Country/Region (2018-2023) 4.2.1 Global Antitumor API Annual Sales by Country/Region (2018-2023) 4.2.2 Global Antitumor API Annual Revenue by Country/Region (2018-2023) 4.3 Americas Antitumor API Sales Growth 4.4 APAC Antitumor API Sales Growth 4.5 Europe Antitumor API Sales Growth 4.6 Middle East & Africa Antitumor API Sales Growth 5 Americas 5.1 Americas Antitumor API Sales by Country 5.1.1 Americas Antitumor API Sales by Country (2018-2023) 5.1.2 Americas Antitumor API Revenue by Country (2018-2023) 5.2 Americas Antitumor API Sales by Type 5.3 Americas Antitumor API Sales by Application 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Antitumor API Sales by Region 6.1.1 APAC Antitumor API Sales by Region (2018-2023) 6.1.2 APAC Antitumor API Revenue by Region (2018-2023) 6.2 APAC Antitumor API Sales by Type 6.3 APAC Antitumor API Sales by Application 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Antitumor API by Country 7.1.1 Europe Antitumor API Sales by Country (2018-2023) 7.1.2 Europe Antitumor API Revenue by Country (2018-2023) 7.2 Europe Antitumor API Sales by Type 7.3 Europe Antitumor API Sales by Application 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Antitumor API by Country 8.1.1 Middle East & Africa Antitumor API Sales by Country (2018-2023) 8.1.2 Middle East & Africa Antitumor API Revenue by Country (2018-2023) 8.2 Middle East & Africa Antitumor API Sales by Type 8.3 Middle East & Africa Antitumor API Sales by Application 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Antitumor API 10.3 Manufacturing Process Analysis of Antitumor API 10.4 Industry Chain Structure of Antitumor API 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Antitumor API Distributors 11.3 Antitumor API Customer 12 World Forecast Review for Antitumor API by Geographic Region 12.1 Global Antitumor API Market Size Forecast by Region 12.1.1 Global Antitumor API Forecast by Region (2024-2029) 12.1.2 Global Antitumor API Annual Revenue Forecast by Region (2024-2029) 12.2 Americas Forecast by Country 12.3 APAC Forecast by Region 12.4 Europe Forecast by Country 12.5 Middle East & Africa Forecast by Country 12.6 Global Antitumor API Forecast by Type 12.7 Global Antitumor API Forecast by Application 13 Key Players Analysis 13.1 Acebright 13.1.1 Acebright Company Information 13.1.2 Acebright Antitumor API Product Portfolios and Specifications 13.1.3 Acebright Antitumor API Sales, Revenue, Price and Gross Margin (2018-2023) 13.1.4 Acebright Main Business Overview 13.1.5 Acebright Latest Developments 13.2 Tapi Teva 13.2.1 Tapi Teva Company Information 13.2.2 Tapi Teva Antitumor API Product Portfolios and Specifications 13.2.3 Tapi Teva Antitumor API Sales, Revenue, Price and Gross Margin (2018-2023) 13.2.4 Tapi Teva Main Business Overview 13.2.5 Tapi Teva Latest Developments 13.3 Heraeus 13.3.1 Heraeus Company Information 13.3.2 Heraeus Antitumor API Product Portfolios and Specifications 13.3.3 Heraeus Antitumor API Sales, Revenue, Price and Gross Margin (2018-2023) 13.3.4 Heraeus Main Business Overview 13.3.5 Heraeus Latest Developments 13.4 Johson Matthey 13.4.1 Johson Matthey Company Information 13.4.2 Johson Matthey Antitumor API Product Portfolios and Specifications 13.4.3 Johson Matthey Antitumor API Sales, Revenue, Price and Gross Margin (2018-2023) 13.4.4 Johson Matthey Main Business Overview 13.4.5 Johson Matthey Latest Developments 13.5 Vinkem Labs 13.5.1 Vinkem Labs Company Information 13.5.2 Vinkem Labs Antitumor API Product Portfolios and Specifications 13.5.3 Vinkem Labs Antitumor API Sales, Revenue, Price and Gross Margin (2018-2023) 13.5.4 Vinkem Labs Main Business Overview 13.5.5 Vinkem Labs Latest Developments 13.6 Chem Genix 13.6.1 Chem Genix Company Information 13.6.2 Chem Genix Antitumor API Product Portfolios and Specifications 13.6.3 Chem Genix Antitumor API Sales, Revenue, Price and Gross Margin (2018-2023) 13.6.4 Chem Genix Main Business Overview 13.6.5 Chem Genix Latest Developments 13.7 Cipla 13.7.1 Cipla Company Information 13.7.2 Cipla Antitumor API Product Portfolios and Specifications 13.7.3 Cipla Antitumor API Sales, Revenue, Price and Gross Margin (2018-2023) 13.7.4 Cipla Main Business Overview 13.7.5 Cipla Latest Developments 13.8 Qilu Pharmaceutial 13.8.1 Qilu Pharmaceutial Company Information 13.8.2 Qilu Pharmaceutial Antitumor API Product Portfolios and Specifications 13.8.3 Qilu Pharmaceutial Antitumor API Sales, Revenue, Price and Gross Margin (2018-2023) 13.8.4 Qilu Pharmaceutial Main Business Overview 13.8.5 Qilu Pharmaceutial Latest Developments 13.9 Hangzhou Haoke Bio-Tech 13.9.1 Hangzhou Haoke Bio-Tech Company Information 13.9.2 Hangzhou Haoke Bio-Tech Antitumor API Product Portfolios and Specifications 13.9.3 Hangzhou Haoke Bio-Tech Antitumor API Sales, Revenue, Price and Gross Margin (2018-2023) 13.9.4 Hangzhou Haoke Bio-Tech Main Business Overview 13.9.5 Hangzhou Haoke Bio-Tech Latest Developments 13.10 Kunming Guiyan Pharmaceutical 13.10.1 Kunming Guiyan Pharmaceutical Company Information 13.10.2 Kunming Guiyan Pharmaceutical Antitumor API Product Portfolios and Specifications 13.10.3 Kunming Guiyan Pharmaceutical Antitumor API Sales, Revenue, Price and Gross Margin (2018-2023) 13.10.4 Kunming Guiyan Pharmaceutical Main Business Overview 13.10.5 Kunming Guiyan Pharmaceutical Latest Developments 13.11 Apotex Pharmachem 13.11.1 Apotex Pharmachem Company Information 13.11.2 Apotex Pharmachem Antitumor API Product Portfolios and Specifications 13.11.3 Apotex Pharmachem Antitumor API Sales, Revenue, Price and Gross Margin (2018-2023) 13.11.4 Apotex Pharmachem Main Business Overview 13.11.5 Apotex Pharmachem Latest Developments 13.12 Dr. Reddy's Laboratories 13.12.1 Dr. Reddy's Laboratories Company Information 13.12.2 Dr. Reddy's Laboratories Antitumor API Product Portfolios and Specifications 13.12.3 Dr. Reddy's Laboratories Antitumor API Sales, Revenue, Price and Gross Margin (2018-2023) 13.12.4 Dr. Reddy's Laboratories Main Business Overview 13.12.5 Dr. Reddy's Laboratories Latest Developments 13.13 Umicore 13.13.1 Umicore Company Information 13.13.2 Umicore Antitumor API Product Portfolios and Specifications 13.13.3 Umicore Antitumor API Sales, Revenue, Price and Gross Margin (2018-2023) 13.13.4 Umicore Main Business Overview 13.13.5 Umicore Latest Developments 14 Research Findings and Conclusion